DGAP-News

Press Release: 4SC's associated company Panoptes Pharma concludes license agreement with Mediolanum for compound PP-001 for inflammatory eye diseases

DGAP-News: 4SC AG / Key word(s): Agreement
Press Release: 4SC's associated company Panoptes Pharma concludes
license agreement with Mediolanum for compound PP-001 for inflammatory
eye diseases

10.02.2015 / 07:30

---------------------------------------------------------------------

Press Release

4SC's associated company Panoptes Pharma concludes license agreement with
Mediolanum for compound PP-001 for inflammatory eye diseases

Planegg-Martinsried, Germany and Vienna, Austria, 10 February 2015 - 4SC
Discovery GmbH, a subsidiary of the biotechnology company 4SC AG
(Frankfurt, Prime Standard: VSC) today announced that its associated
company Panoptes Pharma Ges.m.b.H, Vienna, Austria, has entered into an
agreement with Mediolanum Laboratoires Leurquin S.A., the wholly owned
French subsidiary of the Italian company Mediolanum Farmaceutici S.p.A.

Under the terms of the agreement, Mediolanum will acquire marketing rights
to Panoptes Pharma's PP-001, a small molecule which is currently in
preclinical development as potential next generation treatment for several
inflammatory eye diseases including non-infectious uveitis. Under the terms
of the agreement, Panoptes received an upfront payment, and is eligible for
developmental and sales milestones and royalties on net sales. Mediolanum
will have marketing rights over two main European countries, while Panoptes
will retain marketing rights in all other countries. Other terms of the
deal were not disclosed.

PP-001 was orginally discovered by 4SC Discovery GmbH. In 2013, 4SC
Discovery GmbH transfered the IP rights to PP-001 to Panoptes Pharma and
received a 24.9% equity stake in Panoptes Pharma in return. In addition,
4SC Discovery GmbH is entitled to performance-based milestone payments from
Panoptes Pharma and royalties based on the sales revenue generated with
PP-001.

Franz Obermayr, CEO of Panoptes Pharma stated: "This agreement with
Mediolanum validates and strengthens our development strategy for PP-001.
We have made excellent progress in our PP-001 program at Panoptes and the
partnering with Mediolanum will substantially finance our development
program in the future."

Dr. Daniel Vitt, Managing Director of 4SC Discovery GmbH and Chief
Scientific Officer at 4SC AG, comments: "We are very pleased about the
license agreement of our associate company Panoptes with Mediolanum for the
compound PP-001. This is a great validation of the large innovative and
market potential of PP-001, which was originally discovered by 4SC and
assigned to Panoptes. It thus demonstrates the vast scientific potential of